Engineering CD20 CARs with a Twist.
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
03 02 2023
03 02 2023
Historique:
received:
18
11
2022
accepted:
29
11
2022
pubmed:
13
1
2023
medline:
7
2
2023
entrez:
12
1
2023
Statut:
ppublish
Résumé
CD20 is highly expressed in several types of B-cell lymphoma and is an intuitive target for chimeric antigen receptor (CAR) T-cell therapy. However, with conventional approaches, it has been challenging to provide CD20 CAR designs that confer efficacy in preclinical models and in clinical trials. In this issue, Chen and colleagues report several improved CD20 CARs, developed with minimal deviations from conventional design principles, that confer curative anti-lymphoma efficacy in preclinical models. These novel CD20 CARs enrich the pipeline for clinical development and provide an example of rational CAR design that is informed by insights into the structural biology of CAR domains. See related article by Chen et al., p. 150 (3).
Identifiants
pubmed: 36633575
pii: 715079
doi: 10.1158/2326-6066.CIR-22-0919
doi:
Substances chimiques
Receptors, Antigen, T-Cell
0
Antigens, CD20
0
Adaptor Proteins, Signal Transducing
0
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
142-143Commentaires et corrections
Type : CommentOn
Informations de copyright
©2023 American Association for Cancer Research.